Head and neck squamous cell carcinoma (HNSCC) is one of the most common types of cancer in humans, with an annual incidence of more than 500 000 cases worldwide ([@bib19]). Metastasis not only causes the most cancer deaths but is also the most poorly understood component of cancer pathogenesis ([@bib8]). To acquire motility and invasiveness, carcinoma cells must change many of their epithelial phenotypes to mesenchymal phenotypes, and this process is referred to as the epithelial--mesenchymal transition (EMT). Moreover, recent studies have shown that most EMT processes are regulated by extracellular matrix (ECM) components and soluble growth factors or cytokines. Among these factors, fibroblast growth factors (FGFs) execute diverse functions by binding to and activating members of the FGF receptor family, including FGFR1--4.

Fibroblast growth factor receptor 1 (FGFR1) is a growth factor receptor tyrosine kinase, and these kinases are known regulators of various cellular processes, including proliferation, migration, survival and angiogenesis ([@bib10]). Aberrant expression or irregular activation of these FGFRs is involved in the progression of mammary tumorigenesis ([@bib14]), and mutation of FGFRs is the most common genetic alteration in tumours and is strongly associated with low tumour grade and stage. Furthermore, FGFR protein expression is strongly related to mutation status ([@bib18]); specifically, several recurrent high-level gene amplifications have been identified in breast cancer. Among these genes, *FGFR1* was one of the first genes shown to be amplified in 10% of cancers, including breast cancer. In addition, the amplication of *FGFR1* is associated with early relapse and poor survival ([@bib29]). Therefore, FGFR1 signalling may provide a valuable target for controlling tumour development.

PD173074, a previously described ATP pocket inhibitor, has reportedly shown both high affinity and selectivity for the FGFR family ([@bib20]). However, the roles of FGFR1 and of FGFR1 inhibitors in HNSCC have not yet been examined in detail. Here, we investigated the expression of FGFR1 in HNSCC and the roles of FGFR1 inhibitors in carcinogenesis and the EMT process.

Materials and methods
=====================

Clinical data and tissue samples
--------------------------------

One hundred paraffin-embedded HNSCC samples were retrieved from the pathological files of the Cancer Hospital in Ho Chi Minh City, Vietnam and Hiroshima University Hospital, Japan, following approval by the ethical committees of these institutions. The clinical details and lymph node metastasis status were gathered from the surgical records of patients. Only specimens without radiochemotherapy were selected to avoid possible influences of the treatment modality. We used the histological grading system proposed by [@bib3] to evaluate the histopathological patterns of HNSCC samples ([Table 1](#tbl1){ref-type="table"}).

Immunohistochemistry
--------------------

Unstained 4.5-*μ*m sections were cut from each paraffin block, deparaffinised and rehydrated using routine techniques. Endogenous peroxidase activity was blocked with 0.3% H~2~O~2~ in methanol for 30 min before antigen retrieval by microwave treatment in citrate phosphate buffer for 20 min. The sections were then incubated with a protein block in serum-free solution for 10 min. The sections were incubated overnight at 4 °C with an FGFR1 monoclonal antibody (Abcam, Cambridge, MA, USA) diluted in PBS (1 : 100). After washing three times with PBS, the sections were incubated with appropriate peroxidase-labelled secondary antibodies for 1 h at room temperature. The sections were then labelled by diaminobenzidine and counterstained with Mayer\'s haematoxylin, dehydrated and mounted.

Immunostaining was evaluated based on the proportion of stained cancer cells and the location of the staining. Fibroblast growth factor receptor 1 expression was scored on a semiquantitative scale by evaluating the percentage of stained cells within representative areas of each tumour. For superficial carcinomas, the stained sections were observed throughout the lesion. For advanced large tumours, at least 10 fields including superficial, central and deep invasive areas were observed, and the number of stained cells and staining intensity were evaluated. In each field, we counted at least 300 cells using an eyepiece graticule to prevent recounting. The samples were then divided into two groups: those with negative (\<50% of the cancer cells were stained) and positive staining (over 50% of the cancer cells were stained).

Statistical analysis
--------------------

Correlations between the expression of FGFR1 and the clinicopathological features of HNSCC were examined using a *χ*^2^ test. Statistical analyses were performed using SPSS 21.0 (IBM, Armonk, NY, USA), and statistical significance was defined as *P*\<0.05.

Chemical compounds and biological reagents
------------------------------------------

A selective inhibitor of FGFR1, PD173074, was provided by Sigma-Aldrich (Dorset, UK) and dissolved in dimethyl sulphoxide at a concentration of 1 *μ*[M]{.smallcaps}. The stock solution was stored at −20 °C before use. Basic fibroblast growth factor (bFGF) was purchased from R&D systems (Minneapolis, MN, USA).

c-Jun small interfering RNA (siRNA) (5′-CCUCAGCAACUUCAACCC-3′) was transfected into HOC313 cells using Oligofectamine as per the manufacturer\'s instructions (Invitrogen, Tokyo, Japan).

The following antibodies were used for western blotting and immunohistochemical staining: anti-FGFR1 (Abcam), anti-E-cadherin (BD Transduction Laboratories, Franklin Lakes, NJ, USA), anti-Snail1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-*α*-tubulin (Sigma-Aldrich, St Louis, MO, USA), anti-phospho-ERK1/2, anti-ERK1/2 (Santa Cruz Biotechnology), anti-phospho-p38, anti-p38, anti-phospho-Akt, anti-Akt, anti-phospho-GSK3*β*, anti-GSK3*α*, *β*, anti-phospho-c-Jun (Cell Signaling Technology, Danvers, MA, USA) and anti-*β*-actin (Sigma-Aldrich, Dorset, UK).

Reverse transcription--polymerase chain reaction
------------------------------------------------

Total RNA was isolated and purified from fresh--frozen HNSCC tissues and cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany). The isolated nucleic acids were quantified, and their purity was determined using standard spectrophotometric methods. cDNA was synthesised from 1 *μ*g total RNA using the ReverTra Dash system (Toyobo Biochemicals, Tokyo, Japan). The primer sequences were defined as follows: human N-cadherin, 5′-GACAATGCCCCTCAAGTGTT-3′ (forward) 5′-CCATTAAGCCGAGTGATGGT-3′ (reverse); human E-cadherin, 5′-TGCCCAGAAAATGAAAAAGG-3′  (forward)  5′-GGATGACAGCGTGAGAGA-3′ (reverse); human *α*-smooth muscle actin (*α*-SMA), 5′-CCGGGAGAAAATGACTCAAA-3′  (forward)  5′-GAAGGAATAGCCACGCTCAG-3′  (reverse);  human  cytokeratin19,  5′-TTTGAGACGGAACAGGCTCT-3′  (forward)  5′-AATCCACCTCCACACTGACC-3′  (reverse);  human  fibronectin,  5′-TCCACAAGCGTCATGAAGAG-3′ (forward) 5′-ATACCACACCAGGCTTCAGG-3′ (reverse); human glyceraldehyde dehydrogenase  (GAPDH),  5′-ACAGTCAGCCGCATCTTCTT-3′  (forward)  5′-TTGATTTTGGAGGGATCTCG-3′  (reverse);  human  MMP1,  5′-ATGCTGAAACCCTGAAGGTG-3′  (forward)  5′-CTGCTTGACCCTCAGAGACC-3′ (reverse); human MMP3, 5′-GCAGTTTGCTCAGCCTATCC-3′  (forward)  5′-GAGTGTCGGAGTCCAGCTTC-3′  (reverse);  human  MMP10,  5′-GGCTCTTTCACTCAGCCAAC-3′  (forward)  5′-TCCCGAAGGAACAGATTTTG-3′  (reverse);  human  MMP11,  5′-TAGGTGCCTGCATCTGTCTG-3′  (forward)  5′-TGGCTTTGGAGGATAGCAGT-3′ (reverse); human MMP12, 5′-ACACATTTCGCCTCTCTGCT-3′ (forward) 5′-CCTTCAGCCAGAAGAACCTG-3′ (reverse); human MMP13, 5′-TTGAGCTGGACTCATTGTCG-3′  (forward)  5′-GGAGCCTCTCAGTCATGGAG-3′  (reverse);  human  Snail1,  5′-TTTACCTTCCAGCAGCCCTA-3′  (forward)  5′-CAGTGGGGACAGGAGAAGG-3′ (reverse);  human  Snail2,  5′-CTTTTTCTTGCCCTCACTGC-3′  (forward)  5′-GCTTCGGAGTGAAGAAATGC-3′  (reverse);  human Twist, 5′-GTCCGCAGTCTTACGAGGAG-3′  (forward) 5′-CCAGCTTGAGGGTCTGAATC-3′ (reverse); human Vimentin, 5′-GAGAACTTTGCCGTTGAAGC-3′ (forward) 5′-TCCAGCAGCTTCCTGTAGGT-3′  (reverse);  human  ZEB1,  5′-TGCACTGAGTGTGGAAAAGC-3′  (forward)  5′-TGGTGATGCTGAAAGAGACG-3′  (reverse);  human  ZEB2,  5′-TGCCAAGAGAGGAAGAGGAA-3′  (forward)  5′-GTGTCACTGCGCTGAAGGTA-3′  (reverse).

Aliquots of total cDNA were amplified with 1.25 U of rTaq-DNA polymerase (Qiagen), and amplifications were performed in a PC701 thermal cycler (Astec, Fukuoka, Japan) for 30 cycles after an initial 30 s denaturation at 94 °C, consisting of annealing for 30 s at 60 °C and extension for 1 min at 72 °C for all primers. The amplification reaction products were resolved on 1.2% agarose/TAE gels, separated at 135 mV and visualised by ethidium bromide staining.

Cell lines and cell culture
---------------------------

Six HNSCC cell lines were used for this study. Ho-1-N-1 and Ho-1-U-1 cells were provided by the Japanese Collection of Research Bioresources Cell Bank. HOC313 and HOC621 cells were provided by Prof. Kamata (Hiroshima University, Hiroshima, Japan) ([@bib32]). KOSCC33A and KOSCC25B cells were obtained from Dr SP Hong (Seoul National University, Seoul, South Korea). All cells were maintained in RPMI-1640 or DMEM (Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 10% heat-inactivated FBS (Invitrogen) and 100 U ml penicillin--streptomycin (Gibco, Tokyo, Japan) under 5% CO~2~ in air at 37 °C.

Immunofluorescence
------------------

Cells grown on coverslips were fixed in 4% paraformaldehyde for 10 min at room temperature, rinsed three times with ice-cold PBS and then permeabilised in 0.1% Triton X-100 in PBS for 15 min at room temperature. After rinsing three times with PBS, the coverslips were incubated with the primary antibody in 10% DMEM for 2 h at room temperature, rinsed three times with PBS and then incubated with anti-mouse Alexa594 (1 : 1000; Molecular Probes, Eugene, OR, USA), which served as the secondary antibody. DNA was visualised by DAPI staining. The immunostaining of cell preparations was recorded using an epifluorescence Zeiss Axioplan 2 (Zeiss Inc., Thorwood, NY, USA) microscope attached to a CCD camera.

Proliferation assay
-------------------

Cells were plated in a 24-well plate at 5 × 10^3^ cells per well and cultured in DMEM medium. After 1, 2 and 4 days of culture, the cells were trypsinised and counted using a Coulter Counter (Coulter Electronics, Bedfordshire, UK). Each experiment was repeated at least three times in triplicate wells. The growth curves showed the means and standard deviation of the counted cell number.

*In vitro* invasion assay
-------------------------

The invasive behaviour of cells was measured using a Matrigel invasion assay. Eight-micron cell culture plate inserts (24-well inserts, 8-*μ*m pore size; BD Bioscience, Bedford, MA, USA) were coated with 50 *μ*l Matrigel (1 mg ml; BD Bioscience). All cells were preincubated in media with or without PD173074. One hundred microliters of media containing 2 × 10^4^ cells was added to the upper chamber insert, and 500 *μ*l of DMEM was added to the lower chamber. The cells were incubated for 20 h at 37 °C in 5% CO~2~ humidified air, and cells that passed through the Matrigel were fixed in 10% paraformaldehyde and subsequently stained with Mayer\'s haematoxylin. Cells that did not pass through the Matrigel were removed from the insert with a cotton swab. The membrane of the insert was cut from the insert and fixed onto a slide.

The number of invasive cells was evaluated by counting all invading cells under the microscope ( × 10 magnification), and the results were expressed as averages with the standard error. All assays were performed in triplicate.

Migration (wound healing) assay
-------------------------------

Two million cells from each group were seeded in 60-mm-diameter culture dishes and grown to confluence in complete medium. The cells were then gently scraped with a plastic tip. Photomicrographs were taken at 24 and 48 h after wound formation.

Subcellular fractionation
-------------------------

Cells grown on 10-cm dishes were washed two times and scraped in ice-cold PBS. The cells were then centrifuged for 30 s at 12 000 ***g***, and the supernatant was discarded. The cells were resuspended in ice-cold lysis buffer containing 10 m[M]{.smallcaps} morpholineethanesulphonic acid (MES; pH 6.2), 10 m[M]{.smallcaps} NaCl, 1.5 m[M]{.smallcaps} MgCl~2~, 1 m[M]{.smallcaps} EDTA, 5 M dithiothreitol, 1% Triton X-100 and protease inhibitors. After a 5-min centrifugation step, the supernatant containing the cytoplasmic fraction was removed. The remaining nuclear pellet was washed once with washing buffer (lysis buffer without Triton X-100) and lysed in ice-cold extraction buffer (25 m[M]{.smallcaps} Tris-HCl (pH 10.5), 1 m[M]{.smallcaps} EDTA, 0.5 M NaCl, 5 m[M]{.smallcaps} *β*-mercaptoethanol, 0.5% Triton X-100). The resultant supernatant containing the nuclear fraction was removed.

Western blotting
----------------

The cells were lysed in a buffer containing 50 m[M]{.smallcaps} Tris (pH 7.5), 250 m[M]{.smallcaps} NaCl, 0.1% Triton X (Sigma Chemical Co., St Louis, MO, USA), 1 m[M]{.smallcaps} EDTA, 50 m[M]{.smallcaps} NaF and six proteinase inhibitors (DTT, PMSF, Banadate, TPCK, TLCK and PIN). The protein concentration was determined using the Bradford protein assay (Bio-Rad, Richmond, CA) with bovine serum albumin (Sigma) as the standard. Twenty micrograms of protein was solubilised in Laemmli\'s sample buffer by boiling and subjected to 10% SDS--PAGE electrophoresis, followed by electroblotting onto a nitrocellulose membrane (Schleicher & Schuell, Dasse, Germany). The filter was blocked for 1 h at room temperature with PBS buffer (137 m[M]{.smallcaps} NaCl, 8.1 m[M]{.smallcaps} Na~2~HPO~4~·12 H~2~O, 2.68 m[M]{.smallcaps} KCl, 1.47 m[M]{.smallcaps} KH~2~PO4) containing non-fat dry milk powder. The primary antibodies were diluted in PBS containing 5% non-fat dry milk powder and incubated overnight at 4 °C, and the cells were then washed and incubated with the secondary antibody for 1 h at room temperature. The immunocomplex was visualised with an enhanced chemiluminescence HRP substrate for western blotting (Western Lightning Plus ECL; Perkin-Elmer, Waltham, MA, USA) using a Molecular Imager machine (Bio-Rad, Carlsbad, CA, USA). Blots were stripped in 50 m[M]{.smallcaps} Tris (pH 7.5) and 10 [M]{.smallcaps} urea at 55 °C for 20 min before reprobing.

Results
=======

FGFR1 expression and its correlation with clinicopathological findings
----------------------------------------------------------------------

To examine the role of FGFR1 in the progression of HNSCC, we examined the immunohistochemical expression of FGFR1 and its correlation with the clinicopathological findings in 100 HNSCC cases. Here, we classified low-grade HNSCC as grades I and II and high-grade HNSCC as grades III and IV, according to the classification described by [@bib3] ([Table 1](#tbl1){ref-type="table"}). The correlations between features of FGFR1 expression and the clinicopathological findings, including nuclear polymorphism, pattern of invasion and histopathological grade of HNSCC, are summarised in [Table 2](#tbl2){ref-type="table"}. Fibroblast growth factor receptor 1 was highly expressed in 54 (54%) of 100 HNSCC cases ([Figure 1A](#fig1){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Interestingly, FGFR1 expression significantly correlated with nuclear polymorphism ([Figure 1B](#fig1){ref-type="fig"}), pattern of invasion ([Figure 1C](#fig1){ref-type="fig"}) and histological differentiation ([Figure 1D](#fig1){ref-type="fig"}). Fibroblast growth factor receptor 1 expression was also significantly correlated with the number of mitoses per high-power field (data not shown).

Nuclear localisation of FGFR1 in OSCC cases
-------------------------------------------

Recently, it was shown that FGFR1, a plasma membrane-associated protein, translocates to the cell nucleus along with its ligand bFGF and stimulates a multigene program ([@bib27]). In this study, the immunohistochemical staining results for FGFR1 showed two distinct patterns of FGFR1 expression; FGFR1 was either expressed in the cytoplasm and membrane or in the nucleus and membrane ([Figure 2A](#fig2){ref-type="fig"}). We next analysed the correlation between nuclear FGFR1 expression and clinicopathological features of oral squamous cell carcinoma (OSCC). Interestingly, FGFR1 expression was significantly correlated with nuclear polymorphism ([Figure 2B](#fig2){ref-type="fig"}), pattern of invasion ([Figure 2C](#fig2){ref-type="fig"}) and histological differentiation ([Figure 2D](#fig2){ref-type="fig"}).

Expression of FGFR1 in HNSCC cell lines
---------------------------------------

To investigate the correlation between FGFR1 and EMT, we examined the expression of FGFR1, E-cadherin and EMT master genes, including Vimentin, Snail1, Snail2, ZEB1, ZEB2 and *α*-SMA, in six HNSCC cell lines. Among these cell lines, HOC313, KOSCC25B and KOSCC33A cells showed a loss of E-cadherin expression and prominent expression of Snail1, Snail2, ZEB1 and ZEB2 ([Figure 3B](#fig3){ref-type="fig"}), which is consistent with previous studies showing that HOC313, KOSCC25B and KOSCC33A cells demonstrate spindle morphology, high invasive activity and elevated expression of Snail without E-cadherin expression ([@bib32], [@bib31]; [@bib28]; [@bib16]). As a result, HOC313, KOSCC25B and KOSCC33A cells are considered EMT-induced cell lines. In contrast, three other HNSCC cell lines (HOC621, Ho-1-N-1 and Ho-1-U-1) showed cobblestone-like morphology ([Figure 3A](#fig3){ref-type="fig"}) with strong E-cadherin expression but weak Snail1, Snail2, ZEB1, ZEB2 and Vimentin expression ([Figure 3B](#fig3){ref-type="fig"}). Among the cell lines tested, FGFR1 was strongly expressed in the EMT-induced lines but was very weakly expressed in non-EMT-induced lines ([Figure 3B](#fig3){ref-type="fig"}).

We also examined the localisation of FGFR1 expression in HOC313, KOSCC25B and KOSCC33A cells by performing immunofluorescent staining ([Figure 3C](#fig3){ref-type="fig"}) and western blotting for cytoplasmic and nuclear fractions ([Figure 3D](#fig3){ref-type="fig"}). As shown in [Figures 3C and D](#fig3){ref-type="fig"}, FGFR1 was expressed strongly in the nucleus of KOSCC25B cells, partially in the nucleus of HOC313 cells and weakly in the nucleus of KOSCC33A cells.

PD173074 suppresses the growth and invasion of EMT-induced cancer cells
-----------------------------------------------------------------------

Numerous inhibitors of FGFR1 activation have previously been identified. Here, we examined PD173074, an FGFR1-selective inhibitor and a known inhibitor of FGFR1 kinase activity *in vitro*. This drug showed an IC~50~ of approximately 25 n[M]{.smallcaps} and inhibited the autophosphorylation of FGFR1 in a dose-dependent manner with an IC~50~ ranging from 1 to 5 n[M]{.smallcaps} ([@bib20]). To examine the utility of PD173074 as a therapeutic for HNSCC, we treated EMT-induced cell lines (HOC313, KOSCC25B and KOSCC33A) with 15 n[M]{.smallcaps} PD173074 and counted the number of cells at days 1, 2 and 4 after treatment. PD173074 treatment suppressed the cell growth of EMT-induced cell lines ([Figure 4A--C](#fig4){ref-type="fig"}). Furthermore, using migration and Matrigel invasion assays, we found that PD173074 strongly suppressed the ability of HOC313, KOSCC25B and KOSCC33A cells to invade and migrate ([Figure 5A and B](#fig5){ref-type="fig"}).

PD173074 induces MET through MAPK, GSK3*β* and AP-1 activity
------------------------------------------------------------

Because we observed suppressed invasion in EMT-induced HNSCC cell lines, we investigated the expression of master EMT genes following PD173074 treatment in HOC313 cells. Interestingly, PD173074 treatment concurrently reduced Snail1 and Snail2 expression but induced E-cadherin expression ([Figure 6A](#fig6){ref-type="fig"}). These results were also confirmed at the protein level ([Figure 6B](#fig6){ref-type="fig"}). Furthermore, we assessed invasion *in vitro* using Matrigel as a surrogate basement membrane, as cancer cell interactions with the basement membrane matrix are critical, particularly for the peritoneal invasive route. Therefore, we examined the expression of MMPs and found that the expression levels of several MMPs (MMP3, MMP10, MMP12 and MMP13) were reduced in PD173074-treated HOC313 cells, whereas MMP2 and MMP11 expression remained unchanged ([Figure 6A](#fig6){ref-type="fig"}).

According to the GenBank database (National Center for Biotechnology Information, Bethesda, MD, USA), the genes encoding several EMT master markers and MMPs possess the same activator protein-1 (AP-1) binding site ([Figure 6D](#fig6){ref-type="fig"}). In this study, we sought to assess whether several pathways related to FGFR1 activation may result in the reduced expression of Snail1 and several MMPs, as well as the increased expression of E-cadherin. PD173074 treatment inhibited the activation of ERK1/2, p38 and c-Jun ([Figure 7A](#fig7){ref-type="fig"}) but stimulated the phosphorylation of GSK3*β* ([Figure 7B](#fig7){ref-type="fig"}). However, PD173074 treatment did not affect the activity of Akt ([Figure 7A](#fig7){ref-type="fig"}). These results suggested that PD173074 suppressed the phosphorylation of ERK1/2 and p38, which led to inhibition of c-Jun, a component of AP-1. To better understand the role of AP-1 in MET, we knocked down c-Jun expression by transfecting c-Jun siRNA into HOC313 cells ([Figure 7C](#fig7){ref-type="fig"}) and examined the resultant E-cadherin and Snail1 expression. Interestingly, Snail1 expression was reduced and E-cadherin expression was upregulated 72 h after c-Jun knockdown ([Figure 7D](#fig7){ref-type="fig"}).

Moreover, we observed that PD173074 treatment changed the morphology of HOC313 cells from a spindle-like shape to a cobble stone-like shape ([Figure 6C](#fig6){ref-type="fig"}). The morphology of KOSCC25B and KOSCC33A cells also changed from a spindle- to a cobble stone-like shape, but the mechanism of MET induction in these cells differs from that of HOC313 cells and requires further investigation. [Figure 6E](#fig6){ref-type="fig"} clearly shows that PD173074 treatment induced the formation of adherent junctions within 5 days.

Discussion
==========

Fibroblast growth factor receptors have a key role in the proliferation and differentiation of tumour cells, and recent studies have focused on the role of the FGFR family (especially FGFR3) in carcinogenesis ([@bib18]). In lung and prostate cancer, FGFR1 is implicated as an oncogene whose expression is increased in comparison to normal tissue ([@bib12]; [@bib5]). Furthermore, premalignant prostate cells expressing activated FGFR1 have been shown to drive the progression to malignancy ([@bib1]), yet little is known about the expression and precise role of FGFR1 in head and neck cancer. In this study, we observed high levels of FGFR1 expression by immunohistochemistry in a large number of HNSCC cases and demonstrated that FGFR1 was overexpressed in 54% of HNSCC cases as well as a high proportion of HNSCC cell lines, especially EMT-induced cell lines. Furthermore, FGFR1 expression was localised in the membrane, cytoplasm and nucleus of cancer cells. We found that FGFR1 expression was increased in poorly differentiated HNSCC, which agrees with previously reported findings from a number of different types of carcinoma, such as lung cancer ([@bib5]) and prostate cancer ([@bib12]).

Recent studies have also shown that upon stimulation, cells can endocytose FGFR1 into the cytosol, at which point the receptor translocates to the nucleus along with its ligand, bFGF. Within the nucleus, FGFR1 functions as a general transcriptional regulator that activates and stimulates multigene programs for cell growth and differentiation. [@bib26] demonstrated that nuclear FGFR1 stimulated the transition from G~0~/G~1~ to S phase of the cell cycle. Moreover, nuclear FGFR1 executes the release of CBP (CREB-binding protein) from its inactive complex with RSK1 ([@bib11]), a process shown to upregulate gene activities associated with cell differentiation. Furthermore, the protease granzymeB (GrB) has been shown to be responsible for the cleavage of FGFR1 and the nuclear localisation of FGFR1 cleavage, leading to the invasion of breast cancer cells into the stroma ([@bib9]). Our findings showed that a significant increase in FGFR1 nuclear localisation in SCC cells correlated with high-grade histopathology, abundant nuclear polymorphism and a high-grade invasion pattern. Conversely, [@bib5] found that the nuclear expression of FGFR1 correlated significantly with worsened overall survival and recurrence-free survival. We suspect that nuclear FGFR1 may promote invasion and metastasis and that the aberrant nuclear expression of FGFR1 could serve as a marker to predict the malignant behaviour of HNSCC.

Small-molecule inhibitors (PD173074, tyrosine kinase inhibitor (TKI)-258 and SU5402) have recently been used successfully to target FGFR3 in multiple myeloma and urothelial carcinoma both *in vitro* and in animal models ([@bib13]; [@bib18]). PD173074, a synthetic compound of pyrido-\[2,3-*d*\] and a highly selective TKI of FGFR1, competes with ATP binding sites located in the intracellular domain of FGFR1 ([@bib20]) and was used in this study as a selective inhibitor of FGFR1.

In this study, PD173074 treatment suppressed the growth, migration and invasion of EMT-induced HNSCC cell lines ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}). Moreover, PD173074 treatment also reduced the expression of Snail, MMP3, MMP10, MMP12 and MMP13, but induced the expression of E-cadherin. On the basis of the GenBank database, we found that the promoter regions of *SNAI1*, *SNAI2*, *MMP3*, *MMP10*, *MMP12* and *MMP13* contain an AP-1 binding site ([Figure 6D](#fig6){ref-type="fig"}), whereas MMP2 and MMP11 do not contain a conserved AP-1 site. The AP-1 transcription factor is formed by either the homodimerisation of two jun proteins (c-jun, JunB, JunD) or the heterodimerisation of jun and fos proteins through the 'leucine zipper\', and this transcription factor regulates a number of genes that drive tumour promotion and progression ([@bib2]). An alteration in AP-1 composition either directly or indirectly regulates transactivation and DNA-binding activity, which in turn pushes normal cells into a premalignant or malignant state. Previous studies have shown that a component of AP-1 is highly expressed in malignant cervical tissues ([@bib24]), and the basal activity level of AP-1 is known to be important for normal cell proliferation and cell survival. However, overactive c-Jun and c-Fos have recently been recognised to have a key role in malignant transformation ([@bib25]).

In this study, the expression of several MMPs (MMP3, MMP10, MMP12 and MMP13), which contain an AP-1 binding site, was reduced following PD173074 treatment in comparison to control cells. Conversely, the expression of MMP2 and MMP11 remained unchanged in response to PD173074 treatment ([Figure 6A](#fig6){ref-type="fig"}). In general, the expression of MMPs is regulated by transcription factors that are stimulated by growth factors, cytokines and chemical agents such as phorbol esters, physical stress, oncogenic transformation and cell--cell and cell--ECM interactions. The downregulation of MMPs (MMP3, MMP7, MMP9, MMP12 and MMP13) following PD173074 treatment in this study may be related to AP-1, as the results in [Figures 7A and B](#fig7){ref-type="fig"} suggest that PD173074 inhibited ERK1/2 and p38 activation, which diminished the phosphorylation of c-Jun, a component of AP-1. Furthermore, these actions inhibited the transcriptional induction of AP-1-dependent genes, such as *MMP3*, *MMP12* and *MMP13*.

In addition, cellular changes driven by EMT that generate mesenchymal-like cancer cells are thought to have a major role in tumour progression. The central role of E-cadherin loss in EMT has been illustrated in many studies ([@bib30]), and the expression of E-cadherin and Snail, a transcription factor described as a direct repressor of E-cadherin, inversely correlates with the prognosis of patients suffering from breast cancer or OSCC. Furthermore, loss of E-cadherin expression is frequently observed during tumour progression in most epithelial cancers ([@bib7]), and we previously demonstrated that methylation of E-cadherin is involved in invasion and metastasis in HNSCC ([@bib17]).

Moreover, the induction of Snail1 expression has been observed in all previously reported EMT processes ([@bib22]; [@bib4]), and increased Snail1 levels have been correlated with more invasive tumour types ([@bib6]). While repressing epithelial gene expression, Snail proteins activate the expression of the mesenchymal proteins fibronectin and vitronectin ([@bib6]; [@bib23]). Snail1 also drives the expression of the ECM proteins type III and V collagen ([@bib21]). Here, we found that PD173074 suppressed the expression of Snail1 and concurrently induced the expression of E-cadherin ([Figures 6A and B](#fig6){ref-type="fig"}). On te basis on the GenBank database, *Snail1* and *Snail2* also possess AP-1 binding sites in their promoters ([Figure 6D](#fig6){ref-type="fig"}); however, the relationship between AP-1 and Snail in MET has not yet been reported. To determine whether there was a relationship between AP-1 and Snail1 expression, we knocked down c-Jun and examined the resultant expression of E-cadherin and Snail1. Interestingly, Snail1 expression was reduced, whereas E-cadherin expression was induced, 72 h following knockdown of c-Jun.

In addition, Snail is regulated according to its subcellular localisation through GSK3*β*-mediated phosphorylation. GSK3*β* binds to and phosphorylates Snail at two consensus motifs to dually regulate the function of this protein, and the phosphorylation by GSK3*β* leads to the degradation of Snail ([@bib33]). Our results indicate that Snail1 expression was inhibited, whereas E-cadherin expression was increased and formed adherent cell--cell junctions. We speculate that this process may be regulated by two pathways. First, PD173074 may have suppressed ERK1/2 and p38 activation, which inhibited c-Jun phosphorylation and thus reduced Snail1 expression; second, PD173074 may have stimulated GSK3*β* activity, which could have inhibited the transcription of Snail1 but induced parallel E-cadherin expression.

As our results have shown, the interaction between an epithelial cell and its neighbouring cell at adherent junctions contributes to the regulation of cell shape, migration, proliferation and differentiation. The chief components of adherent junctions in epithelial cells are E-cadherin and *β*-catenin ([@bib15]). Loss of cellular adhesion is frequently observed during tumour metastasis, and we observed that HOC313 cells with a spindle shape not only adopted a cobblestone-like morphology ([Figure 6C](#fig6){ref-type="fig"}) but also showed increased E-cadherin expression ([Figure 6A and B](#fig6){ref-type="fig"}) to form adherent junctions between cells in response to PD173074 treatment ([Figure 6E](#fig6){ref-type="fig"}). This phenomenon may suppress the invasive ability of HOC313 cells.

On the basis of our results, we speculate that PD173074 may alter the characteristics of EMT-induced cells towards MET induction, in an attempt, thereby controlling malignant behaviours such as the growth, invasion and metastasis of cancer cells. Thus, PD173074 may potentially represent an approach for the treatment of HNSCC.
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![**Expression of FGFR1 and its correlation to clinicopathological findings in HNSCC.** (**A**) Immunohistochemical staining of FGFR1 in HNSCC. The upper panel shows a lower magnification ( × 40), and the lower panel shows a higher magnification ( × 200). (**B**) Correlation between FGFR1 expression and nuclear polymorphism (little and abundant). The graph shows the percentage of cases with positive or negative expression of FGFR1 in each group (little or abundant nuclear polymorphism). (**C**) Correlation between FGFR1 expression and the pattern of invasion (low grade and high grade). The graph shows the percentage of cases with positive or negative expression of FGFR1 in each group (high- or low-grade invasive pattern). (**D**) Correlation between FGFR1 expression and the histopathological grade (well, moderate and poorly differentiated). The graph shows the percentage of cases with positive or negative expression of FGFR1 in each group (well and moderate or poorly expressed for each histopathological grade).](bjc2013550f1){#fig1}

![**Expression of nuclear FGFR1 and its correlation with clinicopathological findings in HNSCC.** (**A**) Positive expression pattern of FGFR1 at higher magnification ( × 200). The upper panel shows positive expression of FGFR1 in the membrane and cytoplasm of cancer cells. The lower panel shows positive expression of FGFR1 in the nuclei of cancer cells. (**B**) Correlation between FGFR1 expression in the nucleus and nuclear polymorphism (little and abundant). The graph shows the percentage of cases with nuclear or non-nuclear expression of FGFR1 in each group (high or low nuclear polymorphism). (**C**) Correlation between FGFR1 expression and the pattern of invasion (low grade and high grade). The graph shows the percentage of cases with nuclear or non-nuclear expression of FGFR-1 in each group (high- or low-grade invasive pattern). (**D**) Correlation between nuclear FGFR1 expression and the histopathological grade (well, moderate or poorly differentiated). The graph shows the percentage of cases with nuclear or non-nuclear expression of FGFR1 in each group (well and moderate or poorly expressed for each histopathological grade).](bjc2013550f2){#fig2}

![**Expression of FGFR1 in HNSCC cell lines.** (**A**) Morphology of HNSCC cells. The upper panel shows the morphology of EMT-induced cells (HOC313, KOSCC25B and KOSCC33A), and the lower panel shows the morphology of non-EMT-induced cells (HOC621, Ho-1-N-1 and Ho-1-U1). (**B**) The expression of FGFR-1, N-cadherin, E-cadherin, Snail-1, Snail-2 and *α*-SMA was examined by reverse transcription--polymerase chain reaction (RT-PCR) in EMT-induced cells (HOC313, KOSCC25B and KOSCC33A) and non-EMT-induced cells (HOC621, Ho-1-N-1 and Ho-1-U-1). GAPDH expression was used as a positive control. (**C**) Localisation of FGFR1 expression was examined by immunofluorescent staining in HOC313, KOSCC25B and KOSCC33A cells. (**D**) The localisation of FGFR1 expression was examined by western blotting of the subcellular fraction of EMT-induced cells (HOC313, KOSCC25B and KOSCC33A), and GAPDH and LaminB1 expression was used as a positive control. Abbreviation: DAPI=4′,6-diamidino-2-phenylindole.](bjc2013550f3){#fig3}

![**A decrease in cell growth was measured using proliferation assays with HOC313 cells (*P*=0.003) or KOSCC25B cells (*P*=0.001) and KOSCC33A cells (*P*=0.003) upon treatment with 15 n[M]{.smallcaps} PD173074.** Five thousand cells were plated in each well and cultured in Dulbecco\'s modified Eagle\'s medium (DMEM). After 1, 2 and 4 days of treatment, cells were trypsinised and counted. Similar results were obtained in three independent experiments. Data represent the means±s.d. (*n*=3).](bjc2013550f4){#fig4}

![**PD173074 inhibited cancer cell invasion and migration.** (**A**) A decrease in invasive ability measured using the Matrigel invasion assay in HOC313 cells upon treatment with 15 n[M]{.smallcaps} PD173074 after 20 h incubation. \**P*\<0.01; \*\**P*\<0.05. Twenty thousand cells in 100 *μ*l Dulbecco\'s modified Eagle\'s medium (DMEM) with or without PD173074 were plated in Matrigel-coated inserts with an 8 *μ*m pore size. Following culture in 500 *μ*l DMEM for 20 h, cells on the lower surface of the insert membrane were fixed, stained with haematoxylin and counted. Similar results were obtained in three independent experiments. Data represent the means±s.d. (*n*=3). (**B**) A decrease in migration ability was measured using the migration wound healing assay in HOC313 cells upon treatment with 15 n[M]{.smallcaps} PD173074 for 24 or 48 h. Two million cells were plated 24 h before PD173074 treatment and were then scraped with a plastic tip. Photomicrographs were taken at 24 and 48 h after wound formation.](bjc2013550f5){#fig5}

![**PD173074 induced MET.** (**A**) The expression of EMT master genes, MMPs and major epithelial markers was examined by reverse transcription--polymerase chain reaction (RT--PCR) in HOC313 cells upon treatment without or with 15 n[M]{.smallcaps} PD173074B after 1, 2, 3, 4, 5 and 6 days. GAPDH expression was used as a positive control (Cont). (**B**) The expression of E-cadherin and Snail-1 was analysed by western blotting upon treatment without or with 15 n[M]{.smallcaps} PD173074B for 1, 2, 3, 4, 5 and 6 days. Anti-*β*-actin was used as a loading control. (**C**) Cell morphological changes. Upper panel, cell morphology was analysed by fluorescent microscopy according to the immunolocalisation of F-actin at day 5 with or without PD173074 treatment. (**D**) Activator protein-1 (AP-1) binding sites in the promoter of EMT master genes. (**E**) *β*-Catenin expression and adherent junctions in HOC313 cells were examined by immunofluorescent staining at day 5 after PD173074 treatment (15 n[M]{.smallcaps}). DAPI, 4′,6-diamidino-2-phenylindole.](bjc2013550f6){#fig6}

![**PD173074 induced MET through mitogen-activated protein kinase (MAPK) and glycogen synthase kinase 3β (GSK3*β*).** (**A**) HOC313 cells were pretreated with 10 n[M]{.smallcaps} bFGF for 10 min and were then further treated with PD173074 (15 n[M]{.smallcaps}) for 1 h. The phosphorylation of ERK1/2, p38, c-Jun and Akt was examined by western blotting. Anti-*β*-actin was used as a loading control (Cont). (**B**) HOC313 cells were pretreated with 10 n[M]{.smallcaps} bFGF for 10 min and were then further treated with PD173074 (15 n[M]{.smallcaps}) for 1, 2, 3, 6 and 12 h. The phosphorylation of GSK3*β* was examined by western blotting. Anti-GSK3*α*,*β* were used as loading controls. (**C**) The expression of c-Jun was examined by reverse transcription--polymerase chain reaction (RT--PCR) after 48 and 72 h of c-Jun siRNA treatment in HOC313 cells. GAPDH expression was used as a positive control. (**D**) The expression of Snail1 and E-cadherin was analysed by western blotting after 48 and 72 h of c-Jun siRNA treatment in HOC313 cells. Anti-*β*-actin was used as a loading control.](bjc2013550f7){#fig7}

###### Histopathological grading based on the system proposed by Anneroth *et al* (1987)

                                                                             **Points**                                                                                                                                                                                                          
  -------------------------------------------------------------------------- -------------------------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  **Histological grading of malignancy among the tumour cell population**                                                                                                                                                                                                                        
  Degree of keratinisation                                                   Highly keratinised (\>50% of the cells)            Moderately keratinised (20--50% of the cells)                     Minimally keratinised (5--20% of the cells)                                                    No keratinisation (0--5% of cells)
  Nuclear polymorphism                                                       Little nuclear polymorphism (\>75% mature cells)   Moderately abundant nuclear polymorphism (50--75% mature cells)   Abundant nuclear polymorphism (25--50% mature cells)                                           Extreme nuclear polymorphism (0--25% mature cells)
  Number of mitoses/HPF                                                      0--1                                               2--3                                                              4--5                                                                                           \>5
  **Histological grading of malignancy for the tumour--host relationship**                                                                                                                                                                                                                       
  Pattern of invasion                                                        Pushing, well-delineated infiltrating borders      Infiltrating, solid cords, bands and/or strands                   Small groups or cords of infiltrating cells (*n*\>15)                                          Marked and widespread cellular dissemination in small groups of cells (*n*\<15) and/or single cells
  Stage of invasion (depth)                                                  Carcinoma *in situ* and/or questionable invasion   Distinct invasion, but involving the lamina propria only          Invasion below the lamina propria adjacent to muscles, salivary gland tissues and periosteum   Extensive and deep invasion replacing most of the stromal tissue and infiltrating the jaw bone

Abbreviation: HPF=high-power field.

The sum of the scores was graded as grade I (4--8), grade II (9--12) and grade III (13--16).

###### Summary of the clinicopathological features of the studied HNSCC cases

  **Feature**                    **HNSCC (n=100)**
  ----------------------------- -------------------
  Mean age (range, years)         58.93 (22--92)
  **Sex**                       
  Male                               27 (27%)
  Female                             73 (73%)
  **Histopathological grade**   
  Well/moderate                      69 (69%)
  Poor                               31 (31%)
  **FGFR1 expression**          
  Cytoplasm+membrane                 28 (28%)
  Nuclear+membrane                   26 (26%)
  Negative                           46 (46%)

Abbreviations: FGFR1=fibroblast growth factor receptor; HNSCC=head and neck squamous cell carcinoma.
